On June 8, 2022 Alvotech Holdings SA ("Alvotech SA"), a global biotech company focused exclusively on developing and manufacturing biosimilar drugs for patients worldwide, and Oaktree Acquisition Corp. II ("OACB") (NYSE: OACB), a special purpose acquisition company sponsored by a subsidiary of Oaktree Capital Management, LP ("Oaktree"), reported that their previously announced business combination between Alvotech SA, OACB and the legal entity named Alvotech, previously named Alvotech Lux Holdings SAS, with Alvotech as its surviving entity (the "Business Combination") was approved by the shareholders of OACB in (Press release, Alvotech, JUN 8, 2022, View Source [SID1234615774])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

It is expected that the Business Combination will be completed (on or about) June 15, 2022, subject to the satisfaction of all other applicable closing conditions. Alvotech’s common stock is expected to trade under the ticker symbol "ALVO" on the Nasdaq Stock Market in New York and the Nasdaq First North Growth Market in Reykjavik, and Alvotech’s warrants are expected to trade on the Nasdaq Stock Market in New York under the mnemo "ALVOW".

"This is an exciting time for the Alvotech team, our partners, and anyone who wants more affordable, high-quality biologic medicines," said Robert Wessman, Founder and Chairman of the Board of Alvotech. "Since the company was founded a decade ago, we have been dedicated to expanding patient access to life-changing treatments."

"Alvotech becomes a publicly traded company at a pivotal time for the healthcare industry globally, when demand for increased affordability and accessibility has never been greater," said Zaid Pardesi, Director Financier and Head of M&A, Oaktree Acquisition Corp II. "We are proud of this partnership with a company that is transforming the lives of patients and improving the sustainability of healthcare systems, and we look forward to continuing to work alongside the Alvotech team to achieve their goal of become a leading provider of biosimilars in all major global markets."

On June 8, 2022 Biogen Inc. (Nasdaq: BIIB) reported that it is unable to participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022, due to considerations related to COVID (Press release, Biogen, JUN 8, 2022, View Source [SID1234615773]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On June 8, 2022 Provectus (OTCQB: PVCT) reported that updated data from the Company’s initial expansion cohort of patients with uveal melanoma metastatic to the liver (mUM) in its cancers-of-the-liver Phase 1 trial of investigational immunocatalyst PV-10 (rose bengal sodium) (NCT00986661) were presented at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, held June 3-7 in Chicago, Illinois and online (Press release, Provectus Biopharmaceuticals, JUN 8, 2022, View Source [SID1234615772]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Twenty-nine percent (29%) of Stage IV M1a mUM patients achieved mCR and were alive from 12.4+ to 48.8+ months after starting PV-10 treatment. All M1a patients had hepatic metastases injected with PV-10; 50% had extrahepatic disease, which was not injected with PV-10. A portion of M1a patients underwent positron emission tomography (PET)-computed tomography (CT) (PET-CT) cancer imaging, which previously has not been widely recognized as an important tool for monitoring tumor response in mUM because historical treatments essentially did not produce mCRs.

This ongoing single-center mUM study at MD Anderson Cancer Center (MDACC) in Houston, Texas has been led since inception by Sapna Patel, MD, Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine at MDACC. Up to three hepatic mUM tumors can be injected per PV-10 treatment cycle. Response assessments are performed at Day 28, and then every three months. Patients with additional, injectable, visceral hepatic mUM disease may receive additional cycles of PV-10 after Day 28. Eligible patients may also receive standard of care immune checkpoint blockade (CB; i.e., either PD-1 or combination CTLA-4 + PD-1) during and after PV-10 treatment.

Highlights from the ASCO (Free ASCO Whitepaper) presentation, with data supplementation

PV-10 can induce mCR in injected/adscopal and non-injected/abscopal lesions.
mCR suggests immunogenic cell death in mUM patients with non-injected liver metastases.
RECIST response assessment may underestimate the effect of PV-10 in injected tumors. 2D EASL is more sensitive than RECIST to changes in injected lesions. PET-CT is more sensitive than either RECIST or 2D EASL.
Translational research is underway at MDACC and Moffitt Cancer Center to elucidate the molecular basis for mCR responders vs non-responders.
A copy of the ASCO (Free ASCO Whitepaper) poster presentation is available on Provectus’ website at: View Source

Ed Pershing, Chair of Provectus’ Board of Directors (Board), said, "We could not be more grateful to these study patients, their families and caregivers, the MD Anderson Cancer Center clinical trial team, and the ocular melanoma patient advocacy community for the opportunity to better develop a comprehensive approach for identifying, surveilling, treating, and hopefully defeating this terrible disease in its early metastatic stage. We have gained valuable insights from this clinical trial that will be considered for future patient assessment and treatment protocols, as we continue to advance PV-10 for the treatment of metastatic uveal melanoma."

Dominic Rodrigues, Vice Chair of the Board, added, "These clinical trial data show that, while PV-10 can contribute to treatment efficacy across all disease stages, PV-10 may have much greater impact on early-stage metastatic uveal melanoma. It is important to note that patients do not typically present with M1a, M1b, or M1c disease, and that staging of study participants is based on the status of their metastatic disease course at the start of PV-10 treatment. The outcome in M1a patients who achieved a metabolic complete response implies that early intervention can be critical, and that surveillance techniques like PET imaging can play an essential role in identifying metastatic status and assessing treatment response."

Mr. Rodrigues concluded, "Metastatic uveal melanoma can be particularly threatening once it takes hold at metastatic sites around the body. These study data give us a level of confidence that the potential exists to provide a survival benefit to patients with metastatic disease by leveraging standard of care immunotherapy in combination with PV-10, and to finalize the development of a PV-10-led approach that could offer durable responses in patients by proactively integrating assessment and treatment methodologies earlier and not waiting for a patient’s disease to get out of control."

On Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") reported that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the Goldman Sachs 43rd Annual Global Healthcare Conference being held in Rancho Palos Verdes, CA on June 14-16, 2022 (Press release, Halozyme, JUN 8, 2022, View Source [SID1234615771]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs 43rd Annual Global Healthcare Conference

A live audio webcast of the presentation will be available in the Investor Relations section of the Company’s website. Replays of the audio webcast will be available for 90 days following the conference.

On June BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, reported that Julia Wang, Chief Financial Officer, and Angus Grant, Ph.D., Chief Business Executive, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 8:40 a.m. PT (Press release, BeiGene, JUN 8, 2022, View Source [SID1234615770]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed from the investors section of BeiGene’s website at View Source, View Source or View Source An archived replay will be available for 90 days following the event.